Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model
Michal Wegrzynowicz, Dana Bar-On, Laura Calo', Oleg Anichtchik, Mariangela Iovino, Jing Xia, Sergey Ryazanov, Andrei Leonov, Armin Giese, Jeffrey W Dalley, Christian Griesinger, Uri Ashery, Maria Grazia Spillantini, Michal Wegrzynowicz, Dana Bar-On, Laura Calo', Oleg Anichtchik, Mariangela Iovino, Jing Xia, Sergey Ryazanov, Andrei Leonov, Armin Giese, Jeffrey W Dalley, Christian Griesinger, Uri Ashery, Maria Grazia Spillantini
Abstract
Parkinson's disease (PD) is characterized by the presence of α-synuclein aggregates known as Lewy bodies and Lewy neurites, whose formation is linked to disease development. The causal relation between α-synuclein aggregates and PD is not well understood. We generated a new transgenic mouse line (MI2) expressing human, aggregation-prone truncated 1-120 α-synuclein under the control of the tyrosine hydroxylase promoter. MI2 mice exhibit progressive aggregation of α-synuclein in dopaminergic neurons of the substantia nigra pars compacta and their striatal terminals. This is associated with a progressive reduction of striatal dopamine release, reduced striatal innervation and significant nigral dopaminergic nerve cell death starting from 6 and 12 months of age, respectively. In the MI2 mice, alterations in gait impairment can be detected by the DigiGait test from 9 months of age, while gross motor deficit was detected by rotarod test at 20 months of age when 50% of dopaminergic neurons in the substantia nigra pars compacta are lost. These changes were associated with an increase in the number and density of 20-500 nm α-synuclein species as shown by dSTORM. Treatment with the oligomer modulator anle138b, from 9 to 12 months of age, restored striatal dopamine release, prevented dopaminergic cell death and gait impairment. These effects were associated with a reduction of the inner density of large α-synuclein aggregates and an increase in dispersed small α-synuclein species as revealed by dSTORM. The MI2 mouse model recapitulates the progressive dopaminergic deficit observed in PD, showing that early synaptic dysfunction is associated to fine behavioral motor alterations, precedes dopaminergic axonal loss and neuronal death that become associated with a more consistent motor deficit upon reaching a certain threshold. Our data also provide new mechanistic insight for the effect of anle138b's function in vivo supporting that targeting α-synuclein aggregation is a promising therapeutic approach for PD.
Keywords: Alpha-synuclein; Anle138b; Mouse model; Parkinson’s disease; Striatum; Substantia nigra; dSTORM.
Conflict of interest statement
A. G. and C. G. are co-founders of MODAG. A. L. is partly employed by MODAG.
Figures
References
- Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol. 1998;152:879–884.
- Bar-On D, Nachliel E, Gutman M, Ashery U. Dynamic conformational changes in munc18 prevent syntaxin binding. PLoS Comput Biol. 2011;7:e1001097. doi: 10.1371/journal.pcbi.1001097.
- Bar-On D, Wolter S, van de Linde S, Heilemann M, Nudelman G, Nachliel E, et al. Super-resolution imaging reveals the internal architecture of nano-sized syntaxin clusters. J Biol Chem. 2012;287:27158–27167. doi: 10.1074/jbc.M112.353250.
- Bielopolski N, Lam AD, Bar-On D, Sauer M, Stuenkel EL, Ashery U. Differential interaction of tomosyn with syntaxin and SNAP25 depends on domains in the WD40 beta-propeller core and determines its inhibitory activity. J Biol Chem. 2014;289:17087–17099. doi: 10.1074/jbc.M113.515296.
- Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson’s disease, studied with PET. Brain. 1990;113:1539–1552. doi: 10.1093/brain/113.5.1539.
- Calo L, Wegrzynowicz M, Santivanez-Perez J, Grazia Spillantini M. Synaptic failure and alpha-synuclein. Mov Disord. 2016;31:169–177. doi: 10.1002/mds.26479.
- Crowther RA, Jakes R, Spillantini MG, Goedert M. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 1998;436:309–312. doi: 10.1016/S0014-5793(98)01146-6.
- Daher JP, Ying M, Banerjee R, McDonald RS, Hahn MD, Yang L, et al. Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Mol Neurodegener. 2009;4:34. doi: 10.1186/1750-1326-4-34.
- Deacon RM. Measuring motor coordination in mice. J Vis Exp. 2013;75:2609.
- Decressac M, Mattsson B, Lundblad M, Weikop P, Bjorklund A. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis. 2012;45:939–953. doi: 10.1016/j.nbd.2011.12.013.
- Fulterer A, Andlauer TFM, Ender A, Maglione M, Eyring K, Woitkuhn J, et al. Active zone scaffold protein ratios tune functional diversity across brain synapses. Cell Rep. 2018;23:1259–1274. doi: 10.1016/j.celrep.2018.03.126.
- Garcia-Reitbock P, Anichtchik O, Bellucci A, Iovino M, Ballini C, Fineberg E, et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson’s disease. Brain. 2010;133:2032–2044. doi: 10.1093/brain/awq132.
- Garcia-Reitboeck P, Anichtchik O, Dalley JW, Ninkina N, Tofaris GK, Buchman VL, et al. Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra. Exp Neurol. 2013;248:541–545. doi: 10.1016/j.expneurol.2013.07.015.
- Goldberg NR, Hampton T, McCue S, Kale A, Meshul CK. Profiling changes in gait dynamics resulting from progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal lesioning. J Neurosci Res. 2011;89:1698–1706. doi: 10.1002/jnr.22699.
- Heras-Garvin A, Weckbecker D, Ryazanov S, Leonov A, Griesinger C, Giese A, et al. Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord. 2018;34:255–263. doi: 10.1002/mds.27562.
- Hindle JV. Ageing, neurodegeneration and Parkinson’s disease. Age Ageing. 2010;39:156–161. doi: 10.1093/ageing/afp223.
- Jellinger KA, Lantos PL. Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update. Acta Neuropathol. 2010;119:657–667. doi: 10.1007/s00401-010-0672-3.
- Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain. 2013;136:2419–2431. doi: 10.1093/brain/awt192.
- Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci. 2007;27:1405–1410. doi: 10.1523/JNEUROSCI.4564-06.2007.
- Kudwa AE, Menalled LB, Oakeshott S, Murphy C, Mushlin R, Fitzpatrick J, et al. Increased body weight of the BAC HD transgenic mouse model of Huntington’s disease accounts for some but not all of the observed HD-like motor deficits. PLoS Curr. 2013;5:e49838.
- Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol. 2003;62:1241–1253. doi: 10.1093/jnen/62.12.1241.
- Lewis GN, Byblow WD, Walt SE. Stride length regulation in Parkinson’s disease: the use of extrinsic, visual cues. Brain. 2000;123:2077–2090. doi: 10.1093/brain/123.10.2077.
- Martinez Hernandez A, Urbanke H, Gillman AL, Lee J, Ryazanov S, Agbemenyah HY, et al. The diphenylpyrazol compound anle138b blocks A-beta channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Mol Med. 2018;10:32–47. doi: 10.15252/emmm.201707825.
- McFadyen MP, Kusek G, Bolivar VJ, Flaherty L. Differences among eight inbred strains of mice in motor ability and motor learning on a rotorod. Genes Brain Behav. 2003;2:214–219. doi: 10.1034/j.1601-183X.2003.00028.x.
- Morris ME, Iansek R, Matyas TA, Summers JJ. Stride length regulation in Parkinson’s disease. Normalization strategies and underlying mechanisms. Brain. 1996;119:551–568. doi: 10.1093/brain/119.2.551.
- Mouton PR, Gokhale AM, Ward NL, West MJ. Stereological length estimation using spherical probes. J Microsc. 2002;206:54–64. doi: 10.1046/j.1365-2818.2002.01006.x.
- Paumier KL, Sukoff Rizzo SJ, Berger Z, Chen Y, Gonzales C, Kaftan E, et al. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson’s disease. PLoS One. 2013;8:e70274. doi: 10.1371/journal.pone.0070274.
- Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates. Amsterdam: Elsevier Academic Press; 2004.
- Perrin RJ, Payton JE, Barnett DH, Wraight CL, Woods WS, Ye L, et al. Epitope mapping and specificity of the anti-alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines. Neurosci Lett. 2003;349:133–135. doi: 10.1016/S0304-3940(03)00781-X.
- Sigal YM, Zhou R, Zhuang X. Visualizing and discovering cellular structures with super-resolution microscopy. Science. 2018;361:880–887. doi: 10.1126/science.aau1044.
- Specht CG, Schoepfer R. Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci. 2001;2:11. doi: 10.1186/1471-2202-2-11.
- Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad Sci USA. 1998;95:6469–6473. doi: 10.1073/pnas.95.11.6469.
- Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–840. doi: 10.1038/42166.
- Tang AH, Chen H, Li TP, Metzbower SR, MacGillavry HD, Blanpied TA. A trans-synaptic nanocolumn aligns neurotransmitter release to receptors. Nature. 2016;536:210–214. doi: 10.1038/nature19058.
- Tofaris GK, Garcia Reitbock P, Humby T, Lambourne SL, O’Connell M, Ghetti B, et al. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1–120): implications for Lewy body disorders. J Neurosci. 2006;26:3942–3950. doi: 10.1523/JNEUROSCI.4965-05.2006.
- Wagner J, Krauss S, Shi S, Ryazanov S, Steffen J, Miklitz C, et al. Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol. 2015;130:619–631. doi: 10.1007/s00401-015-1483-3.
- Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease. Acta Neuropathol. 2013;125:795–813. doi: 10.1007/s00401-013-1114-9.
- Whiten DR, Zuo Y, Calo L, Choi ML, De S, Flagmeier P, et al. Nanoscopic characterisation of individual endogenous protein aggregates in human neuronal cells. ChemBioChem. 2018;19:2033–2038. doi: 10.1002/cbic.201800209.
Source: PubMed